retatrutide triple agonist obesity phase 2 trial (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist— Obesity, NAFLD, and T2D Results retatrutide phase 2 trial obesity

Vascular endothelial growth factor (VEGF), a typical marker of angiogenesis during wound healing, was quantitatively assessed via ELISA on day 3, revealing a significant increase in the G/D-CuP group (Fig

Lin J-P, Tian J, You J-FF, Jin Z-HH, Xu Z-NN, Cen P-LL, Lin HP, Tian J, You J-FF, Jin Z-HH, Xu Z-NN, Cen P-LL, Lin J-P, Tian J, You J-FF, Jin Z-HH, Xu Z-NN, Cen P-LL (2004) An effective strategy for the co-production of S-adenosyl-L-methionine and glutathione by fed-batch fermentation

In the third quarter of 2025 alone, tirzepatide generated US$10.11 billion, eclipsing Mercks Keytruda as the best-selling drug franchise on Earth

Weight loss goals: Larger targets may require a longer treatment phase

GLP-1 300 , 52 , 70%, 1.1 , GLP-1 281.3

Systematic characterization of regulatory variants of blood pressure genes